CRISPR-Cas System: Mechanisms, Therapeutic Potential, and Ethical Perspectives

Table of Contents

• Introduction to CRISPR-Cas system
• Bacterial Adaptive Immunity of the CRISPR
• Structure of the CRISPR Locus
• Mechanism of Action of the CRISPR
• Classification of Systems of the CRISPR
• The Cas9 Enzyme of the CRISPR
• Guide RNA (gRNA) Design of the CRISPR
• Base Editing and Prime Editing of the CRISPR
• Off-Target Effects and Specificity of the CRISPR
• Therapeutic Applications of the CRISPR
• Ethical and Regulatory Landscape of the CRISPR
• Conclusion
• References

Ready Made Presentation

Introduction to CRISPR-Cas system

• The CRISPR-Cas system is a genetic mechanism found in prokaryotes, consisting of specialized DNA sequences called clustered regularly interspaced short palindromic repeats (CRISPR) along with CRISPR-associated (Cas) genes.
• CRISPR sequences were first identified in Escherichia coli in 1987 by researchers at Osaka University, although their origin and biological function were not understood at that time.
• Subsequent research revealed that the CRISPR-Cas system functions as an RNA-mediated defense mechanism in prokaryotes, including bacteria and archaea, protecting them against invading genetic elements such as viruses (bacteriophages) and plasmids.
• Since its discovery, the CRISPR-Cas system has been adapted into a powerful genome editing technology, significantly expanding its applications beyond basic research into areas such as molecular diagnostics and therapeutic interventions.
• Key discoveries related to the CRISPR-Cas9 system and its application in gene editing were recognized with the Nobel Prize in Chemistry in 2020, awarded to Emmanuelle Charpentier and Jennifer Doudna.

Bacterial Adaptive Immunity of the CRISPR

• Bacteria possess multiple innate immunity-like defense mechanisms, including abortive infection, receptor mutation, and restriction-modification systems; however, the CRISPR-Cas system provides a more specialized defense against mobile genetic elements (MGEs) such as plasmids, bacteriophages, transposons, and insertion sequences.
• Although CRISPR sequences were initially discovered in bacteria in 1987, their biological function remained unknown until 2005, when researchers observed that the spacer sequences within CRISPR arrays showed similarity to sequences derived from bacteriophages.
• In 2007, experimental evidence demonstrated that a strain of Streptococcus thermophilus developed resistance to bacteriophages by incorporating new spacer sequences into its CRISPR array following exposure to phages.
• This discovery confirmed that the CRISPR-Cas system functions as an adaptive immune mechanism in bacteria, enabling them to defend against infections caused by bacteriophages and plasmids.
• The CRISPR-Cas system operates by capturing fragments of invading DNA from previous infections, storing them as spacer sequences in the bacterial genome, and subsequently using these genetic “memories” to recognize and specifically target and eliminate invading pathogens based on sequence complementarity.

Structure of the CRISPR Locus

• A CRISPR-Cas system contains a specific DNA region known as the CRISPR locus, which is composed of multiple functional elements that work together in bacterial adaptive immunity.
• The CRISPR array is made up of short, identical, and palindromic repeat sequences, within which unique spacer sequences are interspersed; these spacers are derived from foreign DNA fragments (protospacers), are non-repetitive, and serve as molecular memories that guide the recognition of future invading pathogens, while proteins such as Cas1 and Cas2 are primarily responsible for integrating these spacers into the array.
• The leader sequence is a variable-length, AT-rich region located upstream (adjacent) to the CRISPR array, which plays a crucial role in spacer acquisition by acting as a binding or landing site for the Cas1–Cas2 complex during the integration of new spacers into the CRISPR locus, and it also functions as the primary promoter region for the transcription of CRISPR pre-crRNA.
• CRISPR-associated (Cas) genes encode Cas proteins that are involved in both the integration of foreign DNA into the CRISPR array and the subsequent targeting and elimination of invading genetic elements; these proteins include Cas1, Cas2, Cas9, Cas12, and Cas13, and the corresponding genes are typically located downstream of the CRISPR array.

Mechanism of Action of the CRISPR

The CRISPR-Cas system functions through three major sequential steps:

Adaptation (Spacer Acquisition)

• Adaptation is the process by which foreign DNA fragments (protospacers) are captured and integrated into the CRISPR array as new spacer sequences, typically adjacent to the leader sequence.
• A short 2–5 nucleotide sequence known as the Protospacer Adjacent Motif (PAM) is located next to the protospacer and is essential for the identification and selection of foreign DNA.
• The presence of PAM helps the system distinguish invading genetic material from the host’s own CRISPR sequences, preventing self-targeting.
• The integration of new spacer sequences into the CRISPR array is primarily mediated by the Cas1–Cas2 protein complex across most CRISPR types.

Expression (crRNA Biogenesis)

• Expression, also known as crRNA biogenesis, involves the transcription of the CRISPR array (including repeats and previously acquired spacers) into a long precursor molecule called pre-crRNA.
• This pre-crRNA is then processed and matured by Cas proteins such as Cas5 and Cas6 into shorter, functional crRNA molecules.
• Each mature crRNA contains both spacer-derived sequences (which are complementary to foreign DNA) and repeat-derived sequences.
• The spacer region remains linear, while the repeat sequences fold into stable hairpin or loop-like structures.
• These secondary structures enhance stability by protecting crRNA from degradation by intracellular nucleases.
• The looped structures also facilitate high-affinity binding with Cas proteins, forming crRNA–Cas complexes.
• The crRNA–Cas complex then specifically recognizes and binds to complementary protospacer sequences in invading genetic elements.

Interference

• During the interference stage, the crRNA–Cas protein complex identifies and targets foreign DNA molecules.
• Target recognition occurs through complementary base pairing between the spacer region of crRNA and the protospacer sequence in the presence of PAM sequences.
• The crRNA acts as a guide molecule, directing the complex to the precise target sequence.
• Once binding occurs, Cas nucleases such as Cas9 initiate nucleolytic activity, resulting in double-stranded DNA breaks and cleavage of the target DNA.

Although the overall mechanism of the CRISPR-Cas system is conserved, variations exist among different CRISPR types in terms of the specific Cas proteins and crRNA structures involved, leading to differences in target specificity and mechanistic details across CRISPR systems.

Classification of Systems of the CRISPR

CRISPR-Cas systems are broadly classified into two major classes based on the composition of their effector protein complexes, and these classes are further divided into 6 primary types and more than 30 subtypes.

Class 1 Systems

• Class 1 systems utilize multiprotein effector complexes composed of several Cas proteins and are highly prevalent in both bacteria and archaea, where they primarily target nucleic acids through coordinated action of multiple protein subunits.
• The major types included in Class 1 systems are Type I, Type III, and Type IV.

Type I:

• Type I systems are the most abundant and widely distributed CRISPR-Cas systems.
• The CRISPR-associated complex for antiviral defense (Cascade) is the main effector complex involved in the interference stage.
• The Cascade complex is composed of multiple proteins, including Cas5, Cas6, and Cas7.
• The Cas3 protein plays a crucial role as the primary nuclease responsible for target DNA cleavage.

Type III:

• Type III systems primarily target RNA rather than DNA.
• Cas6 protein is mainly responsible for the cleavage of pre-crRNA.
• The major effector complex is the Csm complex, which consists of Csm/Cas proteins along with crRNA.
• This system includes six subtypes: III-A, III-B, III-C, III-D, III-E, and III-F.

Type IV:

• Type IV systems include effector complex proteins such as Cas5, Cas7, a unique Cas6, and Csf1.
• These systems typically lack Cas proteins required for adaptation and cleavage stages.
• A distinct Cas6 protein is involved in pre-crRNA processing.
• This system comprises three subtypes: IV-A, IV-B, and IV-C.

Class 2 Systems

• Class 2 systems utilize a single, large effector protein for target recognition and cleavage, making them simpler and widely used in genome editing applications.
• The major types included in Class 2 systems are Type II, Type V, and Type VI.

Type II:

• In Type II systems, the Cas9 protein functions as the main effector with two nuclease domains responsible for cleaving target DNA.
• Pre-crRNA processing is mediated by RNase III in combination with trans-activating CRISPR RNA (tracrRNA) and the Cas9 protein.
• This system contains three subtypes: II-A, II-B, and II-C.

Type V:

• Type V systems utilize the Cas12 protein as a single effector complex.
• Cas12 and its associated domains are responsible for recognizing and cleaving target DNA.
• This system includes ten subtypes: V-A, V-B, V-C, V-D, V-E, V-F, V-G, V-H, V-I, and V-K.

Type VI:

• Type VI systems employ Cas13 protein as the effector complex.
• The HEPN domain of Cas13 is responsible for the cleavage of foreign RNA.
• This system consists of four subtypes: VI-A, VI-B, VI-C, and VI-D.

Although all CRISPR-Cas systems follow a general mechanism, variations in effector proteins, target molecules (DNA or RNA), and structural organization lead to differences in functionality and specificity across different classes, types, and subtypes.

The Cas9 Enzyme of the CRISPR

• The Cas9 enzyme is a key component of the Type II CRISPR-Cas system in bacteria and functions as an RNA-guided endonuclease involved in adaptive immunity.
• It recognizes and cleaves foreign nucleic acid sequences that are complementary to the RNA sequence loaded into the enzyme, enabling bacteria to defend against invading genetic elements.
• Cas9 acts as a molecular “scissors,” cutting DNA at precise, targeted locations, which also makes it a powerful tool for genome editing and modification of genetic sequences.
• Structurally, the Cas9 protein contains a PAM-interacting domain that is responsible for recognizing the Protospacer Adjacent Motif (PAM) sequence, which is essential for target identification.
• It also possesses two nuclease domains, the HNH domain and the RuvC domain, both of which work together to cleave the two strands of target DNA.
• The activity of Cas9 depends on its interaction with RNA molecules and specific DNA sequences, functioning in coordination with a single guide RNA (sgRNA) and the presence of a PAM sequence.
• A fully active and functional Cas9 complex consists of the Cas9 nuclease along with CRISPR RNA (crRNA), which provides sequence specificity by targeting a particular DNA locus, and trans-activating CRISPR RNA (tracrRNA), which facilitates structural rearrangement, enabling the binding of crRNA to Cas9 and activating the enzyme.

Guide RNA (gRNA) Design of the CRISPR

• A guide RNA (gRNA), also known as single guide RNA (sgRNA), is a synthetic and engineered RNA molecule formed by combining the natural CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), and it functions to guide the Cas9 nuclease in CRISPR-Cas9 systems to a specific target DNA sequence.
• The primary objective in designing a guide RNA is to achieve high targeting efficiency while minimizing or completely avoiding off-target cleavage within the genome.

Target Region or DNA of Interest

• The specific target region, such as introns, exons, or promoter regions, must be clearly defined prior to designing the gRNA.
• The selection of the target region also depends on the intended application or approach of the CRISPR-Cas system, such as gene knockout, insertion, or regulation.

Type of Cas Protein to be Used

• Different Cas proteins have distinct PAM sequence requirements and mechanisms of DNA cleavage.
• The choice of Cas nuclease influences the design parameters of the gRNA, including its length and the nature of the expected DNA break.

PAM Availability

• A Protospacer Adjacent Motif (PAM) sequence must be present adjacent to the target DNA site for the Cas protein to bind and initiate cleavage.
• The exact position and orientation of the PAM sequence determine where the DNA cleavage will occur relative to the target site.

Testing gRNA for Specificity and Efficiency

• The designed gRNA must be evaluated to ensure high specificity, confirming that it does not bind to similar or homologous sequences elsewhere in the genome.
• This step is critical to prevent unintended off-target effects that could compromise experimental outcomes or therapeutic safety.

gRNA GC Content and Secondary Structure

• Optimal GC content in the gRNA sequence is important for stable hybridization with the target DNA.
• The formation of proper secondary structures within the gRNA enhances its stability and improves its interaction with the Cas nuclease, thereby increasing overall efficiency of genome targeting and cleavage.

Base Editing and Prime Editing of the CRISPR

• Base editing and prime editing are advanced and recently developed CRISPR-Cas-based technologies that enable precise changes in nucleic acid sequences without introducing double-stranded DNA breaks.
• Both base editing and prime editing systems utilize modified Cas proteins that create a single-stranded nick in double-stranded DNA (dsDNA) instead of causing complete double-stranded cleavage.
• Base editing specifically enables the direct conversion of one DNA base into another without double-stranded breakage, allowing for targeted nucleotide substitutions.
• It facilitates transition mutations, including conversions such as cytosine to thymine (C→T), thymine to cytosine (T→C), adenine to guanine (A→G), and guanine to adenine (G→A).
• Prime editing further expands the capabilities of base editing by enabling all types of transversion mutations, including adenine to cytosine (A↔C), adenine to thymine (A↔T), guanine to cytosine (G↔C), and guanine to thymine (G↔T).
• In addition to base substitutions, prime editing also allows for small insertions and deletions within the DNA sequence, increasing its versatility for genome modification.
• These technologies are particularly useful for large-scale genetic corrections, especially in cases where vector-mediated gene delivery is limited due to the restricted gene-carrying capacity of viral vectors.

Off-Target Effects and Specificity of the CRISPR

• Off-target effects in CRISPR occur when the CRISPR-Cas complex cleaves DNA sequences other than the intended target, resulting in unintended modifications.
• Such off-target cleavage can cause insertion or deletion mutations (indels), potentially disrupting normal gene regulation and expression.
• These unintended genetic alterations may lead to harmful consequences, including oncogenic transformation or other deleterious cellular effects.
• Strategies to minimize off-target effects and enhance the specificity of CRISPR-Cas gene editing include optimizing guide RNA (gRNA) design, utilizing high-fidelity Cas9 variants, and employing improved delivery methods for the CRISPR components.

Therapeutic Applications of the CRISPR

• CRISPR-Cas systems have significant therapeutic applications across a range of human diseases and genetic conditions.
• Treatment of genetic blood disorders: CRISPR-Cas-based therapies have shown success in clinical trials for hematological conditions such as sickle cell anemia and β-thalassemia, with the first CRISPR-based therapy receiving approval from the US-FDA.
• Cancer immunotherapy: CRISPR-Cas gene editing is employed to induce multiple knockouts of inhibitory molecules in T-cells, optimizing CAR-T cell function. This allows the engineered T-cells to overcome resistance mechanisms employed by cancer cells and enhances the immune system’s ability to recognize and attack tumors.
• Treatment of monogenic diseases: CRISPR-Cas systems are being explored in pre-clinical studies for correcting single-gene mutations through in vivo genome editing approaches. Disorders targeted include Duchenne muscular dystrophy (DMD) and cystic fibrosis.
• Selective elimination of supernumerary chromosomes: Allele-specific CRISPR applications aim to correct chromosomal abnormalities such as Down syndrome by selectively removing the extra copy of chromosome 21 in trisomic cells.

Ethical and Regulatory Landscape of the CRISPR

• Safety and off-target effects: Unintended off-target mutations caused by CRISPR-Cas systems, which can result in extensive genomic rearrangements, represent a major safety concern in gene editing applications.
• Germline editing concerns: Genome editing in heritable germlines, including eggs, sperm, and embryos, is ethically and socially controversial due to issues related to informed consent, long-term effects on future generations, and potential misuse for eugenics rather than therapeutic purposes.
• Distinguishing enhancement from therapy: A critical ethical challenge lies in differentiating legitimate disease treatment from non-medical modifications or human enhancement, necessitating broad international scientific consensus and ethical guidelines.
• Regulatory bodies: International organizations such as the US-FDA, the European Medicines Agency (EMA), and the World Health Organization (WHO) have established strict guidelines for CRISPR-based gene therapy. These regulations emphasize rigorous pre-clinical evaluation, off-target specificity assessment, research transparency, and prioritize somatic cell applications while prohibiting reproductive or germline genome editing.

Conclusion

• CRISPR-Cas systems have revolutionized genome engineering by harnessing bacterial adaptive immunity and transforming it into a powerful therapeutic platform.
• The clinical potential and applications of CRISPR-based technologies continue to expand across genetic disorders, cancer immunotherapy, and precision medicine.
• Despite these advances, challenges related to targeting specificity, safety concerns, and ethical considerations remain critical and must be addressed.
• Responsible and regulated therapeutic use of CRISPR will ensure its long-term impact on genome editing and the advancement of next-generation medicine.

References

• Barrangou, R., & Marraffini, L. A. (2014). CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Molecular Cell, 54(2), 234–244. https://doi.org/10.1016/j.molcel.2014.03.011
• Feng, X., Li, Z., Liu, Y., Chen, D., & Zhou, Z. (2024). CRISPR/Cas9 technology for advancements in cancer immunotherapy: From uncovering regulatory mechanisms to therapeutic applications. Experimental Hematology & Oncology, 13(1), 102. https://doi.org/10.1186/s40164-024-00570-y
• Gostimskaya, I. (2022). CRISPR-Cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochemistry. Biokhimiia, 87(8), 777–788. https://doi.org/10.1134/S0006297922080090
• Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816–821. https://doi.org/10.1126/science.1225829
• Joseph, C. E., Jain, A., Yaqub, M. O., & Edison, L. K. (2025). CRISPR-Cas systems: Bridging bacterial immunity and host interactions. Applied Microbiology, 5(4), 118. https://doi.org/10.3390/applmicrobiol5040118
• Kalter, N., Fuster-García, C., Silva, A., Ronco-Díaz, V., Roncelli, S., Turchiano, G., Gorodkin, J., Cathomen, T., Benabdellah, K., Lee, C., & Hendel, A. (2025). Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges. Molecular Therapy: Nucleic Acids, 36(3), 102636. https://doi.org/10.1016/j.omtn.2025.102636
• Kantor, A., McClements, M. E., & MacLaren, R. E. (2020). CRISPR-Cas9 DNA base-editing and prime-editing. International Journal of Molecular Sciences, 21(17), 6240. https://doi.org/10.3390/ijms21176240
• Koonin, E. V., & Makarova, K. S. (2024). CRISPR in mobile genetic elements: Counter-defense, inter-element competition and RNA-guided transposition. BMC Biology, 22, 295. https://doi.org/10.1186/s12915-024-02090-x
• Liao, C., Sharma, S., Svensson, S. L., et al. (2022). Spacer prioritization in CRISPR–Cas9 immunity is enabled by the leader RNA. Nature Microbiology, 7, 530–541. https://doi.org/10.1038/s41564-022-01074-3
• Mir, A., Edraki, A., Lee, J., & Sontheimer, E. J. (2018). Type II-C CRISPR-Cas9 biology, mechanism, and application. ACS Chemical Biology, 13(2), 357–365. https://doi.org/10.1021/acschembio.7b00855
• Navarro, C., Díaz, M. P., Durán, P., Castro, A., Díaz, A., Cano, C., Carbonell-Zabaleta, A.-K., Solano-Jiménez, D.-S., Rivera-Porras, D., Contreras-Velásquez, J. C., & Bermúdez, V. (2025). CRISPR-Cas systems: A functional perspective and innovations. International Journal of Molecular Sciences, 26(8), 3645. https://doi.org/10.3390/ijms26083645
• Nidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., & Kuca, K., Tripathi, V. (2021). Novel CRISPR-Cas systems: An updated review of the current achievements, applications, and future research perspectives. International Journal of Molecular Sciences, 22(7), 3327. https://doi.org/10.3390/ijms22073327
• Omer, S. A., Shah, S. A., Garrett, R. A., Saunders, S. J., Costa, F., & Backofen, R. (2016). Characterizing leader sequences of CRISPR loci. Bioinformatics, 32(17), i576–i585. https://doi.org/10.1093/bioinformatics/btw454
• Ryotaro Hashizume, Wakita, S., Sawada, H., Takebayashi, S.-I., Kitabatake, Y., Miyagawa, Y., Hirokawa, Y. S., Imai, H., & Kurahashi, H. (2025). Trisomic rescue via allele-specific multiple chromosome cleavage using CRISPR-Cas9 in trisomy 21 cells. PNAS Nexus, 4(2), pgaf022. https://doi.org/10.1093/pnasnexus/pgaf022
• U.S. Food and Drug Administration. (n.d.). FDA approves first gene therapies to treat patients with sickle cell disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
• Xu, Z., Chen, S., Wu, W., Wen, Y., & Cao, H. (2023). Type I CRISPR-Cas-mediated microbial gene editing and regulation. AIMS Microbiology, 9(4), 780–800. https://doi.org/10.3934/microbiol.2023040